About Patheon
Patheon Inc. (TSX: PTI; www.patheon.com) is a leading provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon provides products and services to more than three hundred of the world's leading pharmaceutical and biotechnical companies. Patheon's technologies and services range from pre-clinical development to manufacturing a full array of dosage forms. Their global network of ten manufacturing facilities and seven development centers ensures that customer products can be launched with confidence anywhere in the world.
Capabilities Overview
- Patheon is a $700 million dollar, publicly traded, globally integrated provider of pharmaceutical development and manufacturing services.
- We work with 20 of the top 30 Big Pharma, as well as 9 of the top 20 specialty pharma companies and 10 of the top 20 biotechs.
- Patheon currently operates a global network of 10 manufacturing facilities, 7 development centers, and numerous sales offices throughout North America, Europe and Asia.
- Patheon provides development services, commercial manufacturing services, and numerous specialized services for our customers. We can help guide your project from pre-formulation all the way to commercialization, and every step in-between.
- Our Commercial Manufacturing units deliver to over 120 countries worldwide and we’re globally compliant with FDA, EMEA, and regulatory bodies in Japan, Brazil, and other countries.
- Twenty-five of today’s Top 200 Prescription Drugs are manufactured by Patheon.
Patheon's commercial manufacturing dosage capabilities:
- Solids in tablets, capsules, and powders
- Liquids & Semi-Solids Capabilities
- Sterile Products Capabilities
- Lyophilization Capabilities
- Nasal Spray Capabilities
- High Potency Capabilities
- Controlled Substances Capabilities
- Analytical: Schedule II, III, III-N to V
- Distribution: Schedule III to V
- Cephalosporin Capabilities
Commercial Manufacturing Services Capacity
- 657 products
- 2,100 SKUs
- Over 4,700 employees worldwide
- 3,000,000 ft² commercial space
- More than 400 million packaged units
- Patheon is a global leader in Product & Analytical Development Services. Our services include pre-formulation, analytical methods, formulation, and scale-up & validation tech transfer.
- Over 550 scientists and support staff
- Including more than 100PhDs
- Over 40 dosage forms
- 7 Global Locations: Whitby & Toronto, Canada; Cincinnati & Raleigh, United States; Swindon & Milton Park, UK and Ferentino, Italy
- Over 250,000 ft² of development space
- Patheon’s Pharmaceutical Development Services have developed 7 of today’s Top 200 Prescription Drugs, generating a combined $3.5 billion a year
- Primary and secondary clinical supplies packaging
- Blinded & multi-language labeling
- Storage
- Global distribution
- Returns
- Reconciliation and destruction
Enhanced services provided by Patheon:
.jpg)
QUICK TO CLINIC™
Patheon offers Quick to Clinic™ programs focused on bringing new molecules to FTIH studies as rapidly as possible while minimizing the amount of API required. Patheon uses the experience and scientific knowledge of its team of Pharmaceutical Development Services (PDS) scientists combined with a number of tools and strategies to achieve these results.
Quick to Clinic™ Dosage Forms:
- Blend in capsule
- API in capsule
- Blend in bottle
- API in bottle
- Tablets
- Oral solutions
Why use Patheon's Quick to Clinic™ service?
- Fast, Flexible, Proven
- Specialized early phase development centers
- Global Network
- No scheduling competition with late phase projects
- Simple, fit for purpose formulations
- Blend in capsule
- API in capsule
- Blend in bottle
- API in bottle
- Tablets
- Oral solutions
.jpg)
The ‘4•6•8 Promise™’
The Quick To Market™ program also introduces its ‘4•6•8 Promise™’. The term is used to highlight the benefits of its rapid development / rapid transfer programs by emphasizing to clients how quickly the work can be done by Patheon while maintaining the high standards of quality that Patheon is known for. The ‘4•6•8 Promise™’, as it is now called, is more adequately described as follows:
- 4: Quick To Clinic™ solid dose molecules will be formulated and ready for distribution to phase 1 clinical trials in just four months from receipt of API.
.jpg)
- 6: Quick To Market™ solid dose or liquid products will be transferred and ready for regulatory filing in just six months from receipt of analytical methods and API. This enables clients to move products very quickly out of their plants and facilitate rationalization programs.
- 8: Quick To Market™ aseptic liquid or lyophilized sterile products will be ready for regulatory filing in just eight months from receipt of analytical methods and API.
|
